Experienced in Budd-Chiari Syndrome

Dr. David Kuter

Hematology
Massachusetts General Physicians Organization Inc
55 Fruit St, 
Boston, MA 
Offers Telehealth
Experienced in Budd-Chiari Syndrome
Massachusetts General Physicians Organization Inc
55 Fruit St, 
Boston, MA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

David Kuter is a Hematologist in Boston, Massachusetts. Dr. Kuter is rated as an Experienced provider by MediFind in the treatment of Budd-Chiari Syndrome. His top areas of expertise are Immune Thrombocytopenic Purpura (ITP), Adult Immune Thrombocytopenia, Thrombocytopenia, Autoimmune Hemolytic Anemia, and Splenectomy.

His clinical research consists of co-authoring 143 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology
Licenses
Internal Medicine in MA
Hospital Affiliations
Newton-Wellesley Hospital
Massachusetts General Hospital
North Shore Medical Center -
Brigham And Women's Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Capital District Physicians Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Mass General Brigham Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

MASSACHUSETTS GENERAL PHYSICIANS ORGANIZATION INC
55 Fruit St, Boston, MA 02114
Other Locations
THE GENERAL HOSPITAL CORPORATION
104 Endicott St, Danvers, MA 01923

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Multicenter, Open-label, Phase IIb Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Rilzabrutinib in Patients With Warm Autoimmune Hemolytic Anemia (LUMINA 2)
A Multicenter, Open-label, Phase IIb Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Rilzabrutinib in Patients With Warm Autoimmune Hemolytic Anemia (LUMINA 2)
Enrollment Status: Active_not_recruiting
Publish Date: May 21, 2025
Intervention Type: Drug
Study Drug: Rilzabrutinib
Study Phase: Phase 2
A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia
A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia
Enrollment Status: Completed
Publish Date: May 25, 2023
Intervention Type: Drug
Study Drug: Fostamatinib
Study Phase: Phase 3
A Phase 1 Safety, Tolerability, and Pharmacokinetics & Pharmacodynamics Study of Multiple- Dose BIVV009 in Patients With Chronic Immune Thrombocytopenia (ITP)
A Phase 1 Safety, Tolerability, and Pharmacokinetics & Pharmacodynamics Study of Multiple- Dose BIVV009 in Patients With Chronic Immune Thrombocytopenia (ITP)
Enrollment Status: Completed
Publish Date: May 18, 2023
Intervention Type: Drug
Study Phase: Phase 1
A Phase 2, Multicenter, Non-Randomized, Open-Label Study of RVT-1401 for the Treatment of Patients With Warm Autoimmune Hemolytic Anemia
A Phase 2, Multicenter, Non-Randomized, Open-Label Study of RVT-1401 for the Treatment of Patients With Warm Autoimmune Hemolytic Anemia
Enrollment Status: Terminated
Publish Date: July 28, 2022
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2, Multi-Center, Open Label, Simon Two-Stage Study to Evaluate the Safety and Efficacy of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia
A Phase 2, Multi-Center, Open Label, Simon Two-Stage Study to Evaluate the Safety and Efficacy of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia
Enrollment Status: Completed
Publish Date: July 21, 2021
Intervention Type: Drug
Study Drug: Fostamatinib
Study Phase: Phase 2
Single-arm Phase 2 Study of Oral Isoquercetin in Sickle Cell Disease
Single-arm Phase 2 Study of Oral Isoquercetin in Sickle Cell Disease
Enrollment Status: Withdrawn
Publish Date: January 11, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Phase 1/2, Open-Label, Dose Escalation Study of PRTX-100 in Adult Patients With Persistent/Chronic Immune Thrombocytopenia
A Phase 1/2, Open-Label, Dose Escalation Study of PRTX-100 in Adult Patients With Persistent/Chronic Immune Thrombocytopenia
Enrollment Status: Terminated
Publish Date: July 05, 2019
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View 6 Less Clinical Trials

143 Total Publications

Evaluating rilzabrutinib in the treatment of immune thrombocytopenia.
Evaluating rilzabrutinib in the treatment of immune thrombocytopenia.
Journal: Immunotherapy
Published: August 11, 2025
Similar Doctors
Advanced in Budd-Chiari Syndrome
Dr. Rasmia A. Ahmed
Hematology Oncology | Hematology | Oncology
Advanced in Budd-Chiari Syndrome
Dr. Rasmia A. Ahmed
Hematology Oncology | Hematology | Oncology

Charles River Medical Associates, PC

571 Union Ave, Suite 202, 
Framingham, MA 
 (19.0 miles away)
508-665-6261
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Rasmia Ahmed is a Hematologist Oncology specialist and a Hematologist in Framingham, Massachusetts. Dr. Ahmed is rated as a Distinguished provider by MediFind in the treatment of Budd-Chiari Syndrome. Her top areas of expertise are Anemia, Myelodysplastic Syndrome (MDS), Thrombocytopenia, and Shwartzman Phenomenon. Dr. Ahmed is currently accepting new patients.

Experienced in Budd-Chiari Syndrome
Dr. David B. Smith
Hematology | Oncology
Experienced in Budd-Chiari Syndrome
Dr. David B. Smith
Hematology | Oncology
55 Fruit St, Yaw 7, 
Boston, MA 
 (0.1 miles away)
617-724-4000
Languages Spoken:
English
See accepted insurances
Accepting New Patients

David Smith is a Hematologist and an Oncologist in Boston, Massachusetts. Dr. Smith is rated as an Advanced provider by MediFind in the treatment of Budd-Chiari Syndrome. His top areas of expertise are Essential Thrombocythemia, Adult Immune Thrombocytopenia, Immune Thrombocytopenic Purpura (ITP), and Autoimmune Hemolytic Anemia. Dr. Smith is currently accepting new patients.

Experienced in Budd-Chiari Syndrome
Dr. Andrea J. Bullock
Hematology
Experienced in Budd-Chiari Syndrome
Dr. Andrea J. Bullock
Hematology

Harvard Medical Faculty Phys At Beth Israel Deaconess Med Ctr Inc

330 Brookline Ave, 
Boston, MA 
 (2.5 miles away)
617-754-8612
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Andrea Bullock is a Hematologist in Boston, Massachusetts. Dr. Bullock is rated as a Distinguished provider by MediFind in the treatment of Budd-Chiari Syndrome. Her top areas of expertise are Pancreatic Ductal Adenocarcinoma, Gallbladder Adenocarcinoma, Non-Muscle Invasive Bladder Cancer, Pancreaticoduodenectomy, and Gamma Knife Radiosurgery. Dr. Bullock is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Kuter's expertise for a condition
ConditionClose
View All 16 Distinguished Conditions
View All 20 Advanced Conditions
View All 36 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile